90816-85-6

Upstream product

• 90816-84-5 1-benzyloxy-4-(3-phthalimidopropoxy)benzene 

Downstream Products

• 705290-31-9 2-[3-(4-oxiranylmethoxy-phenoxy)-propyl]-isoindole-1,3-dione 
• 705290-43-3 2-[3-(3-bromo-4-hydroxy-phenoxy)-propyl]-isoindole-1,3-dione 
• 104652-36-0 2-amino-6-<3-<4-(β-D-galactopyranosyloxy)phenoxy>propylamino>-5-nitrosopyrimidin-4(3H)-one 
• 104652-35-9 3-<4-(β-D-galactopyranosyloxy)phenoxy>propylamine 
• 104652-33-7 N-<3-<4-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyloxy)phenoxy>propyl>phthalimide 
• 104652-34-8 N-<3-<4-(2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyloxy)phenoxy>propyl>phthalimide 
• 25878-60-8 D-galactose pentaacetate 
• 104652-32-6 Acetic acid 4-[3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propoxy]-phenyl ester 

Relevant academic research and scientific papers

COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE

This invention provides compounds that possess inhibitory activity against β--adrenergic receptors and phosphodiesterase PDE, including phosphodiesterase 3 (PDE3 ). This invention further provides pharmaceutical compositions comprising such -compounds; methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine; and methods of preparing pharmaceutical compositions and compounds that possess inhibitory activity against ?-adrenergic receptors and PDE.

Substituted (10H-phenothiazin-10-L)-propyl-1-piperazines

Substituted (10H-phenothiazin-10-yl)propyl-1-piperazines of the formula STR1 wherein R1, R2, R3, A, X, m, n and s are as hereinafter set forth, are described. The compounds of formula I, which contain a piperazine moiety combined by an ether linkage to different phenolic moieties, are useful as orally active long lasting antipsychotic agents.